



California Emerging Infections Program
HUMAN PAPILLOMAVIRUS VACCINE IMPACT MONITORING
(HPV-IMPACT)



June 10, 2022

Dear Colleague,

Thank you for your prior assistance in providing information for surveillance of cervical intraepithelial neoplasia (CIN) 2, 3, and adenocarcinoma in situ (AIS) in Alameda County (HPV-Impact). As a reminder, HPV-Impact began in 2008 and involves surveillance of cervical precancer in adult female residents within Alameda County to monitor impact of the HPV vaccines. It is a collaboration among the Alameda County Department of Public Health (ACDPH), the California Department of Public Health (CDPH), STD Control Branch and the Centers for Disease Control and Prevention (CDC). In September 2013, high-grade cervical precancer was made reportable by ACPHD with case reporting required of histopathology laboratories.

Currently, we are receiving reports of CIN 2, 3, and AIS cases from pathology laboratories that serve your practice, but these reports are often incomplete. **We need your ongoing assistance to provide missing information on these patients including HPV vaccine history, Pap screening history, and demographic data.**

Following this cover letter are case report forms for patients from your practice. **Please have your staff complete any missing information and send back via our confidential fax at (916) 636-6610.** If an item is not available in the chart, please check the corresponding "Unknown" box. **If you have any questions when filling out the forms, please contact Kimberly Gonzalez Barrera, the HPV-Impact Operations Officer, at (510) 406-2036.**

Because CIN2, 3, and AIS are reportable conditions in Alameda County, the State of California Institutional Review Board (IRB) has designated HPV-Impact activities as routine public health surveillance which permits reporting under the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule, 65 F.R. §164.512(b). Patients' individual identifying information is kept strictly confidential and is not shared with outside parties, including the CDC. The most recent approval letter and HIPAA waiver is included. For additional information, please visit the website <http://ceip.us/projects/hpv-impact/>.

Your cooperation and the assistance of your office staff are crucial to the success of this important public health surveillance endeavor. If you have questions or concerns, please contact Dr. Ina Park directly at the phone numbers below. Thank you for your support.

Sincerely,

Ina Park, MD, MS

UC San Francisco School of Medicine

Associate Professor, Family and Community Medicine

Medical Director, California Prevention Training Center

Phone: (510) 625-6012

PLEASE FEEL FREE TO SHARE THIS INFORMATION WITH YOUR OFFICE STAFF.